Mizuho Securities Maintains CVS Health(CVS.US) With Buy Rating, Announces Target Price $66
Barclays lowers CVS Health's target price to $75.
CVS Health Is Maintained at Overweight by Barclays
CVS Health Analyst Ratings
Barclays Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $75
A Quick Look at Today's Ratings for CVS Health(CVS.US), With a Forecast Between $63 to $82
Strategic Leadership Change and Financial Realignment: Reasons Behind CVS Health's Buy Rating
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $75
Truist Financial Maintains CVS Health(CVS.US) With Buy Rating
Analysts Are Neutral on These Healthcare Stocks: CVS Health (CVS), Vertex Pharmaceuticals (VRTX)
Barclays Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $82
CVS Health (CVS) Gets a Buy From Barclays
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $75
BofA Securities Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $77
Analysts' Top Healthcare Picks: Xtant Medical Holdings (XTNT), CVS Health (CVS)
Income Investing: 6 Dividend Stocks to Buy After Tax-Loss Season -- Barron's
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $85
Truist Financial Maintains CVS Health(CVS.US) With Buy Rating, Announces Target Price $76
Barclays has raised the rating and target price of CVS Health.
Barclays has raised the rating and target price of CVS Health.